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Background
Transfer factor is a Dialyzable Leukocyte Extract. It has
been widely used in several clinical scenarios such as
primary immunodeficiencies, infectious diseases and
malignancies with satisfactory results. One of the
mechanisms of action proposed is the enhancement of
the cellular immunity, however this have not yet been
clarified.
Methods
We tested transfer factor in a 1 year old and 3 months
patient diagnosed with Ganglionar Tuberculosis. 1 week
after the administrarion of the Bacillus Calmette-Guérin
vaccination, the present developed fever, cervical, subman-
dibular, supraclavicular, inguinal and axillary lymphadeno-
pathy. Later on the patient devoloped cutaneous clinical
manifestations of tuberculosis such as scrofuloderma, fis-
tulas, hypertrophic scars and ultimately, queloids. The
patient had previously undergone short-term strictly
supervised treatment for tuberculosis with very poor
results. When the treatment was first administered, the
patient had the following data: Total White Blood Count
12.9 Lymphocytes: 29% (12–46) CD3: 26.3% (59–90) T
helper Cells (CD3/CD4) 21.6% (42–58) Cytotoxic T cells
(CD3/CD8) 5.1% (17–33) Natural Killer Cells (CD56) 2.1%
(3–7) B cells (CD19) 67.6 % (0–10).
Results
At the end of the treatment with Transfer Factor the
patient’s immune system was enhanced in terms of cell
count and improval of skin manifestations. Total White
Blood Count 6.5 Lymphocytes: 51.3% CD3: 48.5% T helper
cells(CD3/CD4) 31.2% Cytotoxic T Cells (CD3/CD8)
14.6% Natural Killer cells (CD56) 12.2% B cells (CD19)
985%. Cicatrization process was improved, with involution
of skin lesions os scrofuloderma and fistulas. Lymphade-
nopathy was no longer encountered. We have followed
the patient for a year and half and no relapses have been
encountered.
Conclusions
Transfer Factor may have immunomodulatory properties
and have the potential to be a valuable option as adyuvant
therapy in cases of ganglionar and cutaneous tuberculosis
refractory to conventional treatments. To our knowledge,
as we have previously stated in a WAO forum, this is the
first report of a case of the disease treated satisfactorily
with transfer factor.
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